The specialty of ocular tumor involves the integration of multiple disciplines. With a diverse spectrum of diseases but low incidence rates for individual conditions, it is highly prone to misdiagnosis and suboptimal treatment practices. Thus, rigorous medical quality control is of paramount importance. Pathological diagnosis, regarded as the “gold standard” for disease identification, can significantly enhance early diagnostic efficiency, prevent missed and incorrect diagnoses, and comprehensively improve treatment outcomes for ocular tumors. This can be achieved by intensifying pathological examinations of ocular masses and boosting the specimen submission rate. Based on the scientific prediction of tumors' biological behavior (invasion depth, metastatic potential), treatment response, and prognosis trends by the TNM staging system, clinicians can establish a risk-stratified treatment model, thus optimizing the selection of treatment regimens. To achieve standardized diagnosis and treatment of ocular tumors, it is necessary to focus on promoting the standardized assessment of TNM staging. In conclusion, to improve the diagnosis and treatment of ocular tumors in China, quality control should be strengthened in two aspects: establishing mandatory pathological submission protocols for surgical specimens and improving standardized pretreatment clinical TNM staging assessments. It is also essential to construct standardized diagnostic and therapeutic pathways and quality control networks, promote the homogenization of diagnosis and treatment nationwide, and increase patient survival rates as well as eyeball/visual function preservation outcomes.